Comparison of patients protected to all 7 vaccine serotypes following HCT
| Mo after HCT . | No. vaccine doses received . | Immunized donor group, % (n) . | Unimmunized donor group, % (n) . | P . |
|---|---|---|---|---|
| 3 | 0 | 57 (17/30) | 54 (19/35) | 1.00 |
| 6 | 1 | 67 (16/24) | 36 (10/28)* | .05 |
| 12 | 2 | 60 (12/20) | 35 (9/26) | .14 |
| 13 | 3 | 75 (15/20) | 64 (16/25) | .53 |
| Mo after HCT . | No. vaccine doses received . | Immunized donor group, % (n) . | Unimmunized donor group, % (n) . | P . |
|---|---|---|---|---|
| 3 | 0 | 57 (17/30) | 54 (19/35) | 1.00 |
| 6 | 1 | 67 (16/24) | 36 (10/28)* | .05 |
| 12 | 2 | 60 (12/20) | 35 (9/26) | .14 |
| 13 | 3 | 75 (15/20) | 64 (16/25) | .53 |
The presumed protective antibody concentration to all serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) was 0.5 μg/mL or higher.
Serum not available on one patient.